Torrent Pharma Delivers Solid Q4, Announces ₹6 Dividend Despite Slight Miss on Estimates
Updated: May 20, 2025 17:37
Image Source: Business Today
Torrent Pharmaceuticals has posted a steady performance for the March 2025 quarter, rewarding shareholders with a ₹6 per share dividend even as both revenue and profit came in just below market expectations.
Key Highlights:
Dividend Reward: The board has recommended a final dividend of ₹6 per equity share for FY25, reflecting confidence in the company’s financial strength and commitment to shareholder returns.
Q4 Revenue: Consolidated revenue from operations stood at ₹29.59 billion, narrowly missing the IBES estimate of ₹29.85 billion. The slight shortfall was attributed to moderate growth in the India and Brazil businesses, partially offset by robust performance in the U.S. and Germany.
Net Profit: Q4 consolidated net profit was ₹4.98 billion, just below the IBES estimate of ₹5.19 billion. Margin pressures and increased R&D spending impacted the bottom line, but profitability remains healthy.
Operational Highlights: The India business, a key revenue driver, maintained its growth trajectory, while international markets continued to contribute positively. Torrent’s focus on specialty and chronic therapies, along with new launches, helped cushion the impact of softer segments.
Market Sentiment: Shares traded steady following the announcement, with investors welcoming the dividend and the company’s resilient operational performance amid industry challenges.
Outlook: Management reiterated its commitment to expanding the product pipeline, driving growth in core markets, and maintaining a balanced approach to investments and shareholder rewards.
Torrent Pharma’s Q4 results underscore its stability and focus, with a healthy dividend and solid fundamentals positioning it well for the next phase of growth.
Sources: Moneycontrol, Business Standard, Economic Times